InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,428.09
(
-0.10%
)
US TECH 100
19,144.40
(
0.40%
)
Dow Jones
38,553.96
(
-0.24%
)
Brent Oil
82.41
(
0.53%
)
Bitcoin
65,344.67
(
-2.12%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 82
Posts 12466
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Tuesday, 11/15/2011 11:22:26 AM

Tuesday, November 15, 2011 11:22:26 AM

Post# of 80490
This is too funny. Goldman Sachs upgrades Ariad to neutral, and a price target of $86

Ariad Pharmaceutical (NASDAQ: ARIA) was upgraded by equities research analysts at Goldman Sachs (NYSE: GS) from a “hold” rating to a “neutral” rating in a research note issued to investors on Tuesday. The analysts currently have a $86.00 price target on the stock.


http://localizedusa.com/2011/11/15/ariad-pharmaceutical-aria-shares-upgraded-to-a-neutral-rating-by-goldman-sachs-gs-analysts/
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up